

Clinical trials of Metoprolol

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
Metoprolol vs placebo			
LIT Research Group , 1987 n=1195/1200 follow-up: 18 months	Metoprolol 100 mg bid versus placebo	patients, 45 to 74 years of age, surviving a recent acute MI	Parallel groups Double blind USA
Hjalmarson , 1981 n=698/697 follow-up: 2 years	Metoprolol 100mg twice daily (initial dose intravenously) versus placebo	patients aged between 40 -74 years with suspected MI and onset of infarction within the previous 48h	Parallel groups Double blind Sweden
Manger Cats , 1983 n=273/280 follow-up: 1 year	Metoprolol 100mg twice daily versus placebo	MI, NYHA Class I or II and <=70 y	Parallel groups Double blind Netherlands
Rehnqvist , 1983 n=154/147 follow-up: 36 months	Metoprolol 100mg twice daily versus placebo	AMI patients <70 years in sinus rhythm without complete BBB	Parallel groups Double blind Sweden
Salathia , 1985 n=416/384 follow-up: 1 year	Metoprolol 100 mg twice daily for one year (initial dose intravenously) versus placebo	patients with acute myocardial infarction	Parallel groups Double blind UK
Practolol/metoprolol vs placebo			
Waagstein , 1975 n=38/45 follow-up: 1 week	-	-	Double

More details and results :

- beta-blockers for acute myocardial infarction in immediate beta-blockers at <http://www.trialresultscenter.org/go-Q41>
- beta-blockers for acute myocardial infarction in long term beta-blockers at <http://www.trialresultscenter.org/go-Q42>

References

LIT Research Group , 1987:

The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group Eur Heart J 1987;8:1056-64 [2890522]

Hjalmarson , 1981:

Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmssen L, Wilhelmsson C Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial Lancet 1981;2:823-7 [6116950]

Hjalmarson A, Herlitz J, Holmberg S, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmssen L, Wilhelmsson C The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction Circulation 1983;67:126-32 [6342837]

Am J cardiol 1982; 49:1004 (abstract)

Herlitz J Am J cardiol 1984; 53:1D-50D

Ryden L, Ariniego R, Arnman K, Herlitz J, Hjalmarson A, Holmberg S, Reyes C, Smedgard P, Svedberg K, Vedin A, Waagstein F, Waldenstrom A, Wilhelmsson C, Wedel H, Yamamoto M A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias N Engl J Med 1983;308:614-8 [6828092]

Manger Cats , 1983:

Manger Cats V, van Capelle FJL, Lie KI, Durrer D.nregist Effect of treatment with 2 100 mg metoprolol on mortality in a single-center study with low placebo mortality rate after infarction Circulation 1983;68(suppl 3):181.

Rehnqvist , 1983:

Rehnqvist N, Olsson G. Influence on ventricular arrhythmias by chronic post infarction treatment with metoprolol. appl Circulation 1983;68(suppl 3):69.

Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity J Am Coll Cardiol 1985;5:1428-37 [3889100]

Salathia , 1985:

Salathia KS, Barber JM, McIlmoyle EL, Nicholas J, Evans AE, Elwood JH, Cran G, Shanks RG, Boyle DM Very early intervention with metoprolol in suspected acute myocardial infarction Eur Heart J 1985;6:190-8 [3896811]

Boyle DM, Barber JM, McIlmoyle EL, Salathia KS, Evans AE, Cran G, Elwood JH, Shanks RG Effect of very early intervention with metoprolol on myocardial infarct size Br Heart J 1983;49:229-33 [6338889]

Waagstein , 1975:

Waagstein F, Hjalmarson C Double blind study of the effect of cardioselective - blockade on chest pain in acute myocardial infarction Acta Med Scand 1975;587(suppl):201-11.g

2 heart failure

Trial	Treatments	Patients	Trials design and methods
metoprolol vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
Engelmeier , 1985 n=9/16 follow-up: 12 mo	metoprolol versus placebo	NYHA 2-4, IDC	
BEST (elderly subgroup) , 2001 n=1092	Metoprolol versus placebo	Upper tertile age	
MDC (Waagstein) , 1993 n=194/189 follow-up: 18 months	metoprolol target dose 100-150 mg daily (dose divided into two or three per day) versus placebo	patient with heart failure due to idiopathic dilated cardiomyopathy (NYHA 1-3) and EF<40%	Parallel groups Double blind Europe, North America
Fisher , 1994 n=25/25 follow-up: 6 mo	metoprolol versus placebo	NYHA 3-4, CAD	
Eichhorn , 1994 n=15/9 follow-up: 3 mo	metoprolol versus placebo	NYHA 2-3, IDC	
MERIT-HF , 1999 n=1990/2001 follow-up: 1 y	metoprolol CR/XL at target dose of 200 mg once daily versus placebo	patients with chronic heart failure in New York Heart Association (NYHA) functional class III/IV and with ejection fraction of 0.40 or less, stabilised with optimum standard therapy	Parallel groups Double blind USA and Europe
RESOLVD , 2000 n=214/212 follow-up: 6 mo	metoprolol CR 200 mg/d versus placebo	CHF of mixed causes, patients with symptomatic CHF(NYHA II to IV), a 6-minute walk distance of <500 m, and an LV ejection fraction (EF) of<40%	Parallel groups Double aveugle

More details and results :

- beta-blockers for heart failure in all type of heart failure at <http://www.trialresultscenter.org/go-Q44>
- beta-blockers for heart failure in elderly patients at <http://www.trialresultscenter.org/go-Q119>

References

Engelmeier, 1985:

Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM, Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. *Circulation* 1985; 72:536-46 [3893793]

BEST (elderly subgroup), 2001:

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med* 2001;344:1659-67 [11386264]

MDC (Waagstein), 1993:

Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6 [7902479]

Fisher, 1994:

Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP, Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23:943-50 [8106700]

Eichhorn, 1994:

Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR, Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24:1310-20 [7930255]

MERIT-HF, 1999:

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 1999;353:2001-7 [10376614]

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Go Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283:1295-302 [10714728]

RESOLVD, 2000:

Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000 Feb 1;101:378-84 [10653828]

4

3 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
metoprolol vs placebo			
Kuhlkamp , 2000 n=197/197 follow-up: 6 months	Metoprolol 100 mg/d versus placebo	Persistent AF lasting 2 days to 1 year	Parallel groups double blind

More details and results :

- antiarrhythmic drugs for atrial fibrillation in maintaining sinus rhythm after cardioversion at <http://www.trialresultscenter.org/go-Q113>

References

Kuhlkamp, 2000:

Khilkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-46 [10898425]

4 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
metoprolol vs placebo			
MERIT-HF , 2005 n=495/490 follow-up: 1y	metoprolol CR/XL versus placebo	patients with CHF NYHA classe 2 to 4 and EF<=40% sub group of diabetic patients	Parallel groups double-blind USA and Europe

More details and results :

- anti hypertensive agents for diabetes type 2 in patients with or without hypertension at <http://www.trialresultscenter.org/go-Q414>

References

MERIT-HF, 2005:

Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159-67 [15660048] 10.1016/j.ahj.2004.05.056

CT

Entry terms: metoprolol, Metoprolol, Beloc-Duriles, Beloc Duriles, BelocDuriles, Betalok, Spesicor, Spesikor, H 93-26, H 93 26, H 9326, Lopressor, Metoprolol Tartrate, Seloken, Betaloc, Betaloc-Astra, Betaloc Astra, BetalocAstra, CGP-2175, CGP 2175, CGP2175,